EBMH Editorial

**IF**

Andrea Cipriani,1,2,3 Samuele Cortese,4,5,6,7 Toshi A Furukawa8

1 Department of Psychiatry, University of Oxford, UK

2 Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK

3 Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UK

4 Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK.

5 Solent NHS Trust, Southampton, UK.

6 Department of Child and Adolescent Psychiatry, Hassenfeld Children’s Hospital at NYU Langone, New York, NY, USA.

7 Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK

8 Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Japan

Correspondence to:

Professor Andrea Cipriani

Department of Psychiatry

Warneford Hospital

University of Oxford

OX3 7JX

United Kingdom

When we took the editorship of Evidence-Based Mental Health (EBMH) at the end of 2013, we set two main objectives: to promote and embed an evidence-based medicine (EBM) approach into daily mental health clinical practice and to get an impact factor (IF) for EBMH. Both aims have been big challenges and we have learned a lot.

EBM has been around for about 30 years now, shaping and changing the way we practice medicine. When Gordon Guyatt and colleagues published their seminal paper in 1992,1 EBM was described as the combination of three intersecting domains: the best available evidence, the clinical state and circumstances, and patient’s preferences and values. EBM and EBMH have since continuously evolved to deepen our understanding of these three domains.

*The best available evidence*

We keep complaining about the poor quality of studies in mental health. To properly assess the effects of interventions and devices before and after regulatory approval, we all know that randomised controlled trials are the best study design.2,3 However, real-world data are crucial to shed light on key clinical questions,4 especially when adverse events5 or prognostic factors6 are investigated. It necessarily follows then that, if we want to improve the quality of mental health studies, we first need to improve the type and the quality of the outcome data we collect. There needs to be a joint effort to get reliable patient-reported outcome measures as part of routine care. This is not something we should delegate to professional researchers, but it is something that is up to us and starts in our clinics. The newly established Oxford-Toronto collaboration (a transatlantic agreement between the UK and Canada, led by the Digital and Informatics Theme of the NIHR Oxford Health Biomedical Research Centre) is an excellent example of the full potential of global partnership in designing clinical pathways that collect high-quality outcome data prospectively, using digital technology and taking into account equity, diversity and inclusion (<https://oxfordhealthbrc.nihr.ac.uk/new-transatlantic-partnership-to-transform-research-and-clinical-landscapes-in-mental-health/>).

*The clinical state and circumstances*

The COVID-19 pandemic has reinforced not only the importance of the best science to tackle global threats to humankind,7 but also the close and inextricable link between brain and body.8 We are all aware of it. In our clinics we regularly see people with multiple long-term conditions, with mental health issues as one part of the whole picture. The cross-fertilisation between mental health and other fields of medicine is instrumental to facilitate this integration.9 It is reassuring that many funders internationally now encourage multi-disciplinary collaborations, but, as “modern” mental health professionals, we should challenge our specialised approach, broaden up our interests and strengthen our knowledge in general medicine, neurology, immunology, women’s health and data science (just to mention a few key topics relevant to mental health nowadays). We lack biomarkers in mental health also because historically we have been mainly interested in describing clinical and demographic characteristics, rather than analysing biological or imaging parameters. Genuine curiosity should drive our interests and our practice, so that medicine and mental health will form a virtuous circle.

*Patient’s preferences and values*

There is no doubt that shared decision making between patients, carers and clinicians is the only way forward. The Internet and computer technology help bridge the gap between research evidence and real-world practice in a timely and patient-friendly fashion. However, the big transformation will begin when we truly democratise the field. Mental health professionals should listen more to patients, and patients should become the owners of their healthcare and their data. It goes without saying that questionnaires and surveys are important ways to collect feedback; patients, carers and public should be involved in the co-design and co-development of research projects; but we also need to explore all the relevant ethical implications of the share decision making process. During the COVID-19 pandemic, we have realised how important it is to properly communicate science to lay people to reduce vaccine hesitancy.10 At the same time, when discussing treatment algorithms and clinical decision support tools, trust and trustworthiness are crucial issues to understand and address.

In 2002, a BMJ paper added a fourth dimension to the EBM paradigm: clinical expertise.11 Indeed, EBMH is a journal for clinicians and clinical researchers working in the field of mental health across the lifespan. Now that we finally managed to get an IF (8.141, ranking 13th among psychiatric journals), we will do our best to promote and disseminate the best research to improve clinical practice across the world. It took us almost 8 years of hard work to reach this important achievement. We all know that IF is not the most important parameter for a scientific journal, as it does not automatically represent the quality of the journal. However, the management system and the criteria for IF are more transparent now, and we will continue our efforts to influence clinical practice and research worldwide and simultaneously publish papers that are highly cited.

**References**

1. Guyatt G, Cairns J, Churchill D, et al. Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine. JAMA 1992;268(17):2420–2425. doi:10.1001/jama.1992.03490170092032

2. Naci H, Salcher-Konrad M, Kesselheim AS, Wieseler B, Rochaix L, Redberg RF, Salanti G, Jackson E, Garner S, Stroup TS, Cipriani A. Generating comparative evidence on new drugs and devices before approval. Lancet. 2020;395(10228):986-997. doi: 10.1016/S0140-6736(19)33178-2.

3. Cipriani A, Ioannidis JPA, Rothwell PM, Glasziou P, Li T, Hernandez AF, Tomlinson A, Simes J, Naci H. Generating comparative evidence on new drugs and devices after approval. Lancet. 2020;395(10228):998-1010. doi: 10.1016/S0140-6736(19)33177-0.

4. Vaci N, Liu Q, Kormilitzin A, De Crescenzo F, Kurtulmus A, Harvey J, O'Dell B, Innocent S, Tomlinson A, Cipriani A, Nevado-Holgado A. Natural language processing for structuring clinical text data on depression using UK-CRIS. Evid Based Ment Health. 2020;23(1):21-26. doi: 10.1136/ebmental-2019-300134.

5. Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in people aged 20-64 years: cohort study using a primary care database. BMC Med. 2018 Mar 8;16(1):36. Doi: 10.1186/s12916-018-1022-x.

6. Fazel S, Wolf A, Larsson H, Mallett S, Fanshawe TR. The prediction of suicide in severe mental illness: development and validation of a clinical prediction rule (OxMIS). Transl Psychiatry. 2019;9(1):98. doi: 10.1038/s41398-019-0428-3.

7. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72-74. doi: 10.1016/S0140-6736(20)32623-4.

8. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021;8(5):416-427. doi: 10.1016/S2215-0366(21)00084-5.

9. Cortese S, Solmi M, Arrondo G, Cipriani A, Fusar-Poli P, Larsson H, Correll C. Association between mental disorders and somatic conditions: protocol for an umbrella review. Evid Based Ment Health. 2020;23(4):135-139. doi: 10.1136/ebmental-2020-300158.

10. Smith K, Lambe S, Freeman D, Cipriani A. COVID-19 vaccines, hesitancy and mental health. Evid Based Ment Health. 2021;24(2):47-48. doi: 10.1136/ebmental-2021-300266.

11. Haynes RB, Devereaux PJ, Guyatt GH. Physicians' and patients' choices in evidence based practice. BMJ. 2002;324(7350):1350. doi: 10.1136/bmj.324.7350.1350.